Novartis's Sandoz cleared to launch generic version of Amgen’s Neupogen

Novartis's subsidiary Sandoz has been cleared to launch its biosimilar Zarxio (filgrastim) in September, after the US Court of Appeals for the Federal Circuit declined Amgen's claims.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news